This book explores the theranostic potential of nanoerythrocytes against cancer. It provides a comprehensive overview, beginning with the evolution of erythrocytes into nanoerythrocytes and their crucial role as advanced drug delivery systems in oncology. It addresses the challenges in developing nanoerythrocytes, from safety and scalability to regulatory concerns. It provides a thorough examination of formulation strategies and technological advancements, covering the design, engineering, and optimization of nanoerythrocytes for precise drug delivery. Through case studies, recent patents, and clinical trials, this book reveals the latest advancements and future directions in the field. Furthermore, the chapters discuss the immune responses triggered by nanoerythrocytes and their implications for cancer treatment.

Key Features:

• Explores the theranostic potential of nanoerythrocytes, integrating therapeutic and diagnostic capabilities of nanoerythrocytes for personalized cancer treatment
• Provides detailed insights into the design, drug loading, and release mechanisms that optimize nanoerythrocytes for targeted cancer therapies
• Investigates immune responses to nanoerythrocyte-based treatments, focusing on safety and efficacy in cancer therapy
• Addresses key development challenges-safety, scalability, and regulatory-of using nanoerythrocytes against cancer

• Discusses the latest innovations, patents, and trial outcomes of theranostic potential of nanoerythrocytes against cancer This book is a useful resource for researchers working in cancer biology, pharmaceutical sciences, and biomedical sciences.

  Autorentext

  Dr. Bharti Mangla is working as an Assistant Professor in the Institute of Pharmaceutical Research (IPR), GLA University, Mathura 281406 UP, India. Formerly served as an Assistant Professor in the Department of Pharmaceutics at Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi. She also held the role of Chief Operating Officer (COO) at the DPSRU Innovation and Incubation Foundation. With a doctorate in Pharmaceutics from Jamia Hamdard, New Delhi, Dr. Mangla has a distinguished academic background, having received gold medals at both the undergraduate (B. Pharmacy) and postgraduate (M. Pharmacy in Pharmaceutics) levels from Pandit Bhagwat Dayal Sharma University of Health Sciences, Rohtak. With over eight years of academic and research experience, Dr. Mangla has made significant contributions to formulation development, particularly for diseases such as skin cancer, breast cancer, arthritis, wound healing, and diabetes. She has successfully developed various nanoformulations using different anticancer drugs, specifically targeting skin and breast cancer. Dr. Mangla has filed three patents, authored two international books, contributed five book chapters, and published over 35 international papers in peer-reviewed journals. Dr. Mangla has been honored with several national awards, including recognition for publishing in high-impact journals and for her outstanding performance in poster and oral presentations at conferences.

Prof. Kanchan Kohli is a distinguished academician with a B.Pharmacy and M.Pharmacy from Delhi University and a Ph.D. in Pharmaceutics from Jamia Hamdard. Currently serving as an Adjunct Professor at Gurugram University, Dr. Kohli brings 37 years of combined teaching and research experience, having held positions such as Lecturer, Reader, Senior Lecturer, Professor, and Deputy Director at the All-India Council for Technical Education (AICTE). Dr. Kohli has also served as Director of Research & Publication and was a former Professor at the Department of Pharmaceutics, Jamia Hamdard. Throughout their career, Dr. Kohli has guided 40 Ph.D. and M. Pharm students and has published 270 papers in peer-reviewed journals. Her consultancy work with prominent industries such as Alkem, Patanjali, Cadila Pharmaceuticals, and Amway, along with a submitted BIRAC project in collaboration with the Bio-NEST NIPER-Guwahati Incubation Centre, underscores her contribution to applied research. She has received several prestigious awards, including the UGC Research Award in 2002 and the IPA-ACG SCITECH Innovation Award in 2017. In addition, Dr. Kohli holds 20 international and Indian patents.